TAGRISSO AstraZeneca Pty Ltd
Product name
TAGRISSO
Sponsor
Accepted date
Jul-2024
Active ingredients
osimertinib mesilate
Proposed indication
For the treatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer.
Application type
C (new indication)
Publication date
Jul-2024
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available.